Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Male Breast Carcinoma: Epidemiology, Risk Factors and Current Therapeutic Approaches

  • Zygogianni, Anna G. (Kapodistrian University of Athens, Medical School, 1st Radiology Department, Aretaieion Hospital) ;
  • Kyrgias, George (Thessalia University, Medical School, Radiotherapy Dpt) ;
  • Gennatas, Costantinos (Kapodistrian University of Athens, Medical School, Medical Oncology Unit, Aretaieion Hospital) ;
  • Ilknur, Aytas (Ankara Numune Education and Research Hospital Radiation Oncology Clinic) ;
  • Armonis, Vassilios (IKA Medical Oncology Unit) ;
  • Tolia, Maria (2nd Radiology Department, Attikon Hospital) ;
  • Papaloukas, Christos (AXEPA University Hospital, Radiotherapy, Aristoteleion University) ;
  • Pistevou, Gompaki (AXEPA University Hospital, Radiotherapy, Aristoteleion University) ;
  • Kouvaris, John (Kapodistrian University of Athens, Medical School, 1st Radiology Department, Aretaieion Hospital) ;
  • Kouloulias, Vassilios (2nd Radiology Department, Attikon Hospital)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Male breast cancer is a very rare disease with an incidence of about 0.5-1% comparing with the one of female breast cancer but relatively little is known about its cause. Treatment strategies for breast cancer in males are derived from studies performed among females. The probable reasons behind the frequent, late diagnoses presented at stages III or IV might be the lack of awareness. The rarity of the disease precludes large prospective randomized clinical trials. This study reviews male breast cancer and its risk factors, recommendations for diagnosis and the management of patients with male breast cancer.

Keywords

References

  1. Anderson F, Jatoi I, Tse J, Rosenberg S (2010). Male breast cancer: A population-based comparison with female breast cancer. J Clin Oncol, 28, 232-9. https://doi.org/10.1200/JCO.2009.23.8162
  2. ASCO Working Group on Genetic Testing for Cancer Susceptibility: American Society of Clinical Oncology Policy Statement Update: geneting testing for cancer Susceptibility. (2007) J Clin Oncol, 21, 2397-406.
  3. Bergh J, Jonsson P, Glimelius B, Nygren P (2001). A systematic overview of chemotherapy effects in breast cancer, Acta Oncol, 40, 253-81. https://doi.org/10.1080/02841860151116349
  4. Boughey J, Bedrosian I, Meric-Bernstam F, et al (2006). Comparative analysis of sentinel lymph node operation in male and female breast cancer patients, J Am Coll Surg, 203, 475-80. https://doi.org/10.1016/j.jamcollsurg.2006.06.014
  5. Brinton A, Richesson A, Gierach L, et al (2008). Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst, 100, 1477-81. https://doi.org/10.1093/jnci/djn329
  6. Buzdar A, Ibrahim N, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676-85. https://doi.org/10.1200/JCO.2005.07.032
  7. Chianakwalam C, McCahy P, Griffiths N (2005). A case of male breast cancer in association with bicalutamide-induced gynaecomastia, Breast, 14, 163-4. https://doi.org/10.1016/j.breast.2004.04.007
  8. Cimmino V, Degnim A, Sabel M, et al (2004), Efficacy of sentinel lymph node biopsy in male breast cancer, J Surg Oncol, 86, 74-7. https://doi.org/10.1002/jso.20045
  9. Clarke M, Collins R, Darby S, et al (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials, Lancet, 366, 2087-106. https://doi.org/10.1016/S0140-6736(05)67887-7
  10. Coard K, McCartney T (2004). Bilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence? South Med J, 97, 308-10. https://doi.org/10.1097/01.SMJ.0000050686.54786.79
  11. Contractor B, Kaur K, Rodrigues S, Kulkarni M, Singhal H (2008). Male breast cancer: is the scenario changing. World J Surg Oncol, 6, 58. https://doi.org/10.1186/1477-7819-6-58
  12. Cutuli B (2007). Strategies in treating male breast cancer, Expert Opin Pharmacother, 8, 193-202. https://doi.org/10.1517/14656566.8.2.193
  13. Cutuli B, Lacroze M, Dilhuydy J, et al (1995). Male breast cancer: results of the treatments and prognostic factors in 397 cases, Eur J Cancer, 31A, 1960-4.
  14. Cutuli B, Borel C, Dhermain F, et al (2001). Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases, Radiother Oncol, 59, 247-55. https://doi.org/10.1016/S0167-8140(01)00337-1
  15. Daly B (2009). The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns, 18, 42-8. https://doi.org/10.1007/s10897-008-9183-y
  16. Dicker P (2003). The safety and tolerability of low dose irradiation for the management of gynaecomastia caused by antdrogen monotherapy. Lancet Oncol, 4, 30-6. https://doi.org/10.1016/S1470-2045(03)00958-6
  17. Donegan W, Redlich P, Lang P, Gall M (1998). Carcinoma of the breast in males: a multiinstitutional survey. Cancer, 83, 498-509. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R
  18. Fisher B, Slack N, Katrych D, Wolmark N (1975), Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy, Surg Gynecol Obstet, 140, 528-34.
  19. Forloni F, Giovilli M, Pecis C, et al (2001). Pituitary prolactinsecreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest, 24, 454-9. https://doi.org/10.1007/BF03351047
  20. Gancberg D, Di Leo A, Cardoso F, et al (2002), Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol, 13, 1036-43. https://doi.org/10.1093/annonc/mdf252
  21. Gennari R, Curigliano G, Jereczek-Fossa B, et al (2004). Male breast cancer: a special therapeutic problem. Anything new? Int J Oncol, 24, 663-70.
  22. Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. https://doi.org/10.1002/cncr.20312
  23. Giordano S, Perkins G, Broglio K, et al (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer, 104, 2359-64. https://doi.org/10.1002/cncr.21526
  24. Handesman D (2001). Androgen action and pharmacologic uses. In Endocrinology, 2232-42, Eds Degroot A.
  25. Hooning M, Botma A, Aleman B, et al (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst, 99, 365-75. https://doi.org/10.1093/jnci/djk064
  26. Lanitis S, Rise J, Vaughan A, et al (2008). Diagnosis and management of male breast cancer. World J Surg, 32, 2471-76. https://doi.org/10.1007/s00268-008-9713-7
  27. Levy-Lahad E, Friedman E (2007). Cancer risks among BRCA1 and BRCA2 mutation carriers. BR J Cancer, 96, 11-5. https://doi.org/10.1038/sj.bjc.6603535
  28. Macdonald G, Paltiel C, Olivotto I, Tyldesley S (2005). A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol, 16, 1442-8. https://doi.org/10.1093/annonc/mdi274
  29. Mauras N, O'Brien K, Klein K, Hayes V (2000). Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab, 85, 2370-7. https://doi.org/10.1210/jc.85.7.2370
  30. Meijers-Heijboer H, Van den Ouweland A, Klijn J, et al (2002). CHEK2-Breast Cancer Consortium, Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31, 55-9. https://doi.org/10.1038/ng879
  31. Mohamad B, Apffelstaedt P (2008). Counseling for male BRCA mutation carriers: a review. Breast, 17, 441-50. https://doi.org/10.1016/j.breast.2008.05.001
  32. Nahleh Z (2006), Hormonal therapy for male breast cancer: a different approach for a different disease, Cancer Treat Rev, 32, 101-5. https://doi.org/10.1016/j.ctrv.2005.12.007
  33. Nordenskjold, B Rosell J, Rutqvist L, et al (2005). Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial, J Natl Cancer Inst 97, 1609-10. https://doi.org/10.1093/jnci/dji342
  34. O'Malley C, Prehn A, Shema S, Glaser S (2002). Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer, 94, 2836-43. https://doi.org/10.1002/cncr.10521
  35. Ottini, Rizzolo, Zanna , et al (2009). BRCA1/BRCA2 mutation status and clinical pathologic features of 108 male breast cancer cases from Tuscany: a population based study in central Italy. Breast Cancer Res Treat, 116, 577-86. https://doi.org/10.1007/s10549-008-0194-z
  36. Ottini L, Palli P, Rizzo I, et al (2010). Male breast cancer. Crit Rev Oncol Hematol, 73, 141-55. https://doi.org/10.1016/j.critrevonc.2009.04.003
  37. Pant K, Dutta U (2008). Understanding and management of male breast cancer: a critical review. Med Oncol, 25, 294-98. https://doi.org/10.1007/s12032-007-9034-y
  38. Ribeiro G, Swindell R, Harris M, Banerjee S, Cramer A (1996). A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast, 5, 141-6. https://doi.org/10.1016/S0960-9776(96)90058-2
  39. Romond E, Perez E, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  40. Rossman E, Libjegren A, Bergh J (2007). Male breast cancerhow to treat? Breast Cancer on line, 10, 1-6. https://doi.org/10.4048/jbc.2007.10.1.1
  41. Smith I, Dowsett M, Ebbs S, et al (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate Preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23, 5108-16. https://doi.org/10.1200/JCO.2005.04.005
  42. Smith I, Procter M, Gelber R, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36. https://doi.org/10.1016/S0140-6736(07)60028-2
  43. Swerdlow A, Schoemaker M, Higgins C, et al (2005). Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst, 97, 1204-10. https://doi.org/10.1093/jnci/dji240
  44. Taber Johansen K, Moricy L, Osbahs A, Dickinson B (2010). Male breast cancer: risk factors, diagnosis and management. Oncology Reports, 24, 1115-20.
  45. Thellenberg C, Malmer B, Tavelin B, Gronberg H (2003). Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol, 169, 1345-48. https://doi.org/10.1097/01.ju.0000056706.88960.7c
  46. Trunet P, Mueller B, Bhatnagar A, et al (1993). Open dosefinding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab, 77, 319-23. https://doi.org/10.1210/jc.77.2.319
  47. Turner K, Morley M, Atanassova N, Swanston I, Sharpe R (2000). Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol, 164, 225-38. https://doi.org/10.1677/joe.0.1640225
  48. Vetto J, Jun S, Paduch D, Eppich A, Shih R (1999). Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg, 177, 379-83. https://doi.org/10.1016/S0002-9610(99)00067-7
  49. Willsher P, Leach I, Ellis I, et al (1997). A comparison outcome of male breast cancer with female breast cancer. Am J Surg, 173, 185-8. https://doi.org/10.1016/S0002-9610(97)89592-X
  50. Zabolotny B, Zalai C, Meterissian S (2005). Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol, 90, 26-30. https://doi.org/10.1002/jso.20233

Cited by

  1. Columnar cell-like changes in the male breast vol.67, pp.1, 2014, https://doi.org/10.1136/jclinpath-2013-201631
  2. Male Breast Cancer Clinical Features, Risk Factors, and Current Diagnostic and Therapeutic Approaches vol.05, pp.17, 2014, https://doi.org/10.4236/ijcm.2014.517138
  3. Cancer Awareness among University Students in Turkey vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4289
  4. Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6673
  5. Hormone Receptor Expression and Clinicopathologic Features in Male and Female Breast Cancer vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.471
  6. Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1559
  7. Breast Cancer in Males (BCM), Does It Really Differ? National Cancer Institute Experience (NCI), Cairo University, Egypt vol.07, pp.05, 2016, https://doi.org/10.4236/jct.2016.75037
  8. Male breast cancer arising in ectopic axillary breast tissue: A diagnostic dilemma vol.5, pp.6, 2013, https://doi.org/10.3892/ol.2013.1300
  9. Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso) vol.16, pp.1, 2018, https://doi.org/10.1186/s12957-017-1297-y
  10. Diagnosis and Treatment of Male Breast Tumors vol.08, pp.06, 2018, https://doi.org/10.12677/ACM.2018.86093